Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

Benet, 1996, Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery, J. Control. Release, 39, 139, 10.1016/0168-3659(95)00147-6 Rowland, 1995 Wacher, 1995, Overlapping substrate specificities and tissue distribution of cytochrome P-450 3A and P-glycoprotein have implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog., 13, 129, 10.1002/mc.2940130302 Gomez, 1995, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clin. Pharmacol. Ther., 58, 15, 10.1016/0009-9236(95)90067-5 Floren, 1997, Tacrolimus oral bioavailability doubles with coadministration of ketoconazole, Clin. Pharmacol. Ther., 62, 41, 10.1016/S0009-9236(97)90150-8 Hebert, 1992, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction, Clin. Pharmacol. Ther., 52, 453, 10.1038/clpt.1992.171 Lown, 1997, Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine, Clin. Pharmacol. Ther., 62, 248, 10.1016/S0009-9236(97)90027-8 van Asperen, 1997, Enhanced oral bioavailability of palitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833, Br. J. Cancer, 76, 1181, 10.1038/bjc.1997.530 Salphati, 1998, Effects of ketoconazole on digoxin absorption and disposition in rat, Pharmacology, 56, 308, 10.1159/000028214 Kim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 10.1172/JCI1269 Kim, 1998, Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein, J. Pharmacol. Exp. Ther., 286, 1439 Zhang, 1998, Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor, Drug Metab. Dispos., 26, 360 Shimada, 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians, J. Pharmacol. Exp. Ther., 270, 414 Watkins, 1987, Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man, J. Clin. Invest., 80, 1029, 10.1172/JCI113156 Benet, 1996, Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination, 3 Wacher, 1998, Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics, J. Pharm. Sci., 87, 1322, 10.1021/js980082d Paine, 1997, Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism, J. Pharmacol. Exp. Ther., 283, 1552 Lown, 1998, Sequences of intestinal and hepatic and cytochrome P450 3A4 cDNAs are identical, Drug Metab. Dispos., 26, 185 Lown, 1994, Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by erythromycin breath test, Drug Metab. Dispos., 22, 947 Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem., 62, 385, 10.1146/annurev.bi.62.070193.002125 Fojo, 1987, Expression of a multidrug-resistance gene in human tumors and tissues, Proc. Natl. Acad. Sci. USA, 84, 265, 10.1073/pnas.84.1.265 Lown, 1997, Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression, J. Clin. Invest., 99, 2545, 10.1172/JCI119439 Chang, 1996, Effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers, Clin. Pharmacol. Ther., 59, 297, 10.1016/S0009-9236(96)80007-5 Palmer, 1995, Vinyl sulfones as mechanism-based cysteine protease inhibitors, J. Med. Chem., 38, 3193, 10.1021/jm00017a002 Zhang, 1998, Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague–Dawley rats, J. Pharmacol. Exp. Ther., 287, 246 Wu, 1995, Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine, Clin. Pharmacol. Ther., 58, 492, 10.1016/0009-9236(95)90168-X Gupta, 1989, Cyclosporine–erythromycin interaction in renal transplant patients, Br. J. Clin. Pharmacol., 27, 475, 10.1111/j.1365-2125.1989.tb05396.x Izumi, 1998, A new model for predicting in vivo intestinal metabolism from in vitro data, 83 Thummel, 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism, Clin. Pharmacol. Ther., 59, 491, 10.1016/S0009-9236(96)90177-0 Chiba, 1997, Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A, Biochem. Pharmacol., 53, 1187, 10.1016/S0006-2952(97)00100-7 Fitzsimmons, 1997, Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism, Drug Metab. Dispos., 25, 256 Iatsimirskaia, 1997, Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents, Clin. Pharmacol. Ther., 61, 554, 10.1016/S0009-9236(97)90135-1